Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients - Trial NCT06416436
Access comprehensive clinical trial information for NCT06416436 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Kansas Medical Center and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 54 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Kansas Medical Center
Timeline & Enrollment
Phase 1
May 23, 2024
Jul 01, 2027
Primary Outcome
Maximum tolerated dose of ultra-high dose Stereotactic Ablative Radiotherapy (SBRT) for 3 different body sites
Summary
The purpose of this study is to determine whether cytoreduction of bulky metastatic disease
 using ultra high dose SBRT in combination with immunotherapy is tolerable and feasible In
 patients who have exhausted SoC treatment options.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06416436
Non-Device Trial